HRP20230177T1 - Antigeni citomegalovirusa i njihove uporabe - Google Patents
Antigeni citomegalovirusa i njihove uporabe Download PDFInfo
- Publication number
- HRP20230177T1 HRP20230177T1 HRP20230177TT HRP20230177T HRP20230177T1 HR P20230177 T1 HRP20230177 T1 HR P20230177T1 HR P20230177T T HRP20230177T T HR P20230177TT HR P20230177 T HRP20230177 T HR P20230177T HR P20230177 T1 HRP20230177 T1 HR P20230177T1
- Authority
- HR
- Croatia
- Prior art keywords
- fragment
- protein
- pentamer
- complex
- mutation
- Prior art date
Links
- 241000701022 Cytomegalovirus Species 0.000 title claims 5
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 21
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 7
- 102220510722 Dual specificity tyrosine-phosphorylation-regulated kinase 2_S98G_mutation Human genes 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 102220427461 c.289A>G Human genes 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 108700010903 cytomegalovirus proteins Proteins 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 102200012486 rs111033669 Human genes 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152221.6A EP3048114A1 (en) | 2015-01-22 | 2015-01-22 | Cytomegalovirus antigens and uses thereof |
| PCT/IB2016/050335 WO2016116904A1 (en) | 2015-01-22 | 2016-01-22 | Cytomegalovirus antigens and uses thereof |
| EP16702210.2A EP3247722B1 (en) | 2015-01-22 | 2016-01-22 | Cytomegalovirus antigens and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230177T1 true HRP20230177T1 (hr) | 2023-04-14 |
Family
ID=52434568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230177TT HRP20230177T1 (hr) | 2015-01-22 | 2016-01-22 | Antigeni citomegalovirusa i njihove uporabe |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10167321B2 (enExample) |
| EP (3) | EP3048114A1 (enExample) |
| JP (1) | JP6717836B2 (enExample) |
| KR (1) | KR20170100039A (enExample) |
| CN (1) | CN107531761B (enExample) |
| AU (2) | AU2016210548B2 (enExample) |
| BE (1) | BE1023087B1 (enExample) |
| BR (1) | BR112017015567A2 (enExample) |
| CA (1) | CA2974041C (enExample) |
| DK (1) | DK3247722T5 (enExample) |
| EA (1) | EA038250B1 (enExample) |
| ES (1) | ES2937959T3 (enExample) |
| FI (1) | FI3247722T3 (enExample) |
| HR (1) | HRP20230177T1 (enExample) |
| HU (1) | HUE061175T2 (enExample) |
| IL (1) | IL253366B (enExample) |
| LT (1) | LT3247722T (enExample) |
| MX (1) | MX382518B (enExample) |
| PL (1) | PL3247722T3 (enExample) |
| PT (1) | PT3247722T (enExample) |
| SG (1) | SG11201705740UA (enExample) |
| SI (1) | SI3247722T1 (enExample) |
| WO (1) | WO2016116904A1 (enExample) |
| ZA (1) | ZA201704912B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201802741T4 (tr) * | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CN113528466B (zh) | 2014-07-16 | 2024-12-24 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| SG11201706454VA (en) | 2015-02-10 | 2017-09-28 | Univ Oregon Health & Science | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| WO2017152146A2 (en) | 2016-03-03 | 2017-09-08 | Duke University | Compositions and methods for inducing hiv-1 antibodies |
| WO2018067580A1 (en) | 2016-10-03 | 2018-04-12 | Duke University | Methods to identify immunogens by targeting improbable mutations |
| BR112019007982A2 (pt) | 2016-10-18 | 2019-07-02 | Univ Oregon Health & Science | vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| CA3060019A1 (en) | 2017-04-19 | 2018-10-25 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| US11773144B2 (en) | 2017-10-02 | 2023-10-03 | Duke University | Mosaic HIV-1 envelopes to induce ADCC responses |
| AU2019228551B2 (en) | 2018-02-28 | 2025-07-24 | University Of Washington | Self-assembling nanostructure vaccines |
| EP3773708A2 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
| US12138304B2 (en) | 2018-10-01 | 2024-11-12 | Duke University | HIV-1 envelope stabilizing mutations |
| CA3116175A1 (en) | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| CN109627330A (zh) * | 2018-12-18 | 2019-04-16 | 马鞍山史记动物健康管理有限公司 | 一种猪伪狂犬病毒高效价阳性血清制备方法 |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| CN118580343B (zh) * | 2022-10-21 | 2025-08-19 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1991006667A1 (en) | 1989-11-06 | 1991-05-16 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
| CA2654563A1 (en) | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| EP2352759B1 (en) * | 2008-07-16 | 2017-11-01 | Institute for Research in Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| ES2649896T3 (es) | 2010-07-06 | 2018-01-16 | Glaxosmithkline Biologicals Sa | Emulsiones catiónicas de aceite en agua |
| CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| TWI570240B (zh) * | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| MX378747B (es) | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| US20150359879A1 (en) * | 2012-10-30 | 2015-12-17 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection |
| MX373329B (es) | 2013-12-20 | 2020-05-21 | Novartis Ag | Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés. |
| LT3083676T (lt) | 2013-12-20 | 2019-11-25 | Novartis Ag | Naujos eukariotinės ląstelės, ir dominančio polipeptido rekombinantinės raiškos būdai |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3047856A1 (en) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
-
2015
- 2015-01-22 EP EP15152221.6A patent/EP3048114A1/en not_active Withdrawn
-
2016
- 2016-01-22 EP EP22203406.8A patent/EP4180056A1/en active Pending
- 2016-01-22 FI FIEP16702210.2T patent/FI3247722T3/fi active
- 2016-01-22 SI SI201631665T patent/SI3247722T1/sl unknown
- 2016-01-22 DK DK16702210.2T patent/DK3247722T5/da active
- 2016-01-22 EA EA201791562A patent/EA038250B1/ru unknown
- 2016-01-22 ES ES16702210T patent/ES2937959T3/es active Active
- 2016-01-22 AU AU2016210548A patent/AU2016210548B2/en not_active Ceased
- 2016-01-22 HR HRP20230177TT patent/HRP20230177T1/hr unknown
- 2016-01-22 JP JP2017538387A patent/JP6717836B2/ja active Active
- 2016-01-22 CA CA2974041A patent/CA2974041C/en active Active
- 2016-01-22 SG SG11201705740UA patent/SG11201705740UA/en unknown
- 2016-01-22 BR BR112017015567A patent/BR112017015567A2/pt not_active Application Discontinuation
- 2016-01-22 US US15/544,730 patent/US10167321B2/en active Active
- 2016-01-22 KR KR1020177023123A patent/KR20170100039A/ko not_active Ceased
- 2016-01-22 MX MX2017009538A patent/MX382518B/es unknown
- 2016-01-22 WO PCT/IB2016/050335 patent/WO2016116904A1/en not_active Ceased
- 2016-01-22 EP EP16702210.2A patent/EP3247722B1/en active Active
- 2016-01-22 LT LTEPPCT/IB2016/050335T patent/LT3247722T/lt unknown
- 2016-01-22 HU HUE16702210A patent/HUE061175T2/hu unknown
- 2016-01-22 BE BE2016/5050A patent/BE1023087B1/fr not_active IP Right Cessation
- 2016-01-22 PL PL16702210.2T patent/PL3247722T3/pl unknown
- 2016-01-22 CN CN201680017610.XA patent/CN107531761B/zh active Active
- 2016-01-22 PT PT167022102T patent/PT3247722T/pt unknown
-
2017
- 2017-07-09 IL IL253366A patent/IL253366B/en unknown
- 2017-07-19 ZA ZA2017/04912A patent/ZA201704912B/en unknown
-
2018
- 2018-09-10 AU AU2018226521A patent/AU2018226521B2/en not_active Ceased
- 2018-11-15 US US16/192,347 patent/US20190276498A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230177T1 (hr) | Antigeni citomegalovirusa i njihove uporabe | |
| JP2018504117A5 (enExample) | ||
| BR112017027448A2 (pt) | vacina contra rsv | |
| JP2009540801A5 (enExample) | ||
| HRP20181102T1 (hr) | Cjepiva za hsv-2 | |
| MX2018007860A (es) | Vacunas recombinantes contra el zika. | |
| EA201991093A1 (ru) | Способ повышения уровней секреции интерлейкина-2 и полученных из него белков | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| EP1976871A4 (en) | VACCINES AND IMMUNOTHERAPEUTICS WITH CODON-OPTIMIZED IL-15 AND METHOD OF USE THEREOF | |
| HRP20192050T1 (hr) | Isporuka proteina na bazi bakterija | |
| MX2021004397A (es) | Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos. | |
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| MX2017015927A (es) | Fragmentos mutantes de proteina ras. | |
| PE20180509A1 (es) | Composiciones y metodos para tratar la enfermedad celiaca | |
| JP2012515557A5 (enExample) | ||
| MX380631B (es) | Vectores de adenovirus canino | |
| ME02600B (me) | Imunogena kompozicija | |
| MX2020001655A (es) | Vacuna vph. | |
| JP7762643B2 (ja) | 免疫原性組成物 | |
| NZ769391A (en) | Serpin fusion polypeptides and methods of use thereof | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| HRP20200418T1 (hr) | Terapeutska uporaba koštanih morfogenetičkih proteina | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| JP2019505567A5 (enExample) |